In a report released today, Betsy Graseck from Morgan Stanley maintained a Sell rating on PNC Financial (PNC – Research Report), with a price ...

Says continues to be ‘well-positioned’ with capital flexibility. Says continues to be ‘relatively neutral’ to interest rates in 2025. Says ...

PNC business checking stands out with multiple account options and incentives for new small-business customers. Many, or all, of the products featured on this page are from our advertising ...

In other developments, CRISPR Therapeutics and Vertex Pharmaceuticals continue to advance the launch of the gene-editing therapy Casgevy, despite no revenue generated from the infusion of Casgevy in ...

While Vertex Pharmaceuticals took Casgevy to market, CRISPR Therapeutics AG (NASDAQ: CRSP) was a key collaborator in the development of the treatment, which had a 93.5% effective rate for treating ...

In other developments, CRISPR Therapeutics and Vertex Pharmaceuticals continue to advance the launch of the gene-editing therapy Casgevy, despite no revenue generated from the infusion of Casgevy ...

Vertex already has an approved treatment for sickle cell disease and transfusion-dependent beta thalassemia called Casgevy. However, Casgevy is an ex vivo treatment, meaning patients’ cells are ...

Vertex, which markets the CRISPR therapy Casgevy for sickle cell and beta thalassemia, has been exploring ways to improve on the treatment. In July, the company paid Orum Therapeutics $15 million for ...

The company’s advanced program, Casgevy, is approved for treating severe sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT). CRISPR Therapeutics is headquartered in Zug, ...